Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National institute for translational health (TL1TR001883)
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 25 September 2025
First Online: 24 October 2025
Declarations
:
: This was a retrospective chart review of an IRB approved study and did not require a consent to participate.
: Not applicable for this study.
: VR receives grant funding from Alnylam, Genentech, Merck, Takeda, Blueprint Medicines, Stryker, and Mitsubishi Tanabe. The authors declare that no actual conflicts of interest exist. The other authors hereby declare that they have no potential competing conflicts of interest.
